Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral bromelain + acetylcysteine for unresectable pseudomyxoma peritonei
ACTRN12617001612303Phase 2Recruiting
- Sponsor
- Professor David Morris
- Start
- Feb 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP), mucinous peritoneal tumor and Appendiceal neoplasm, sponsored by Professor David Morris. Primary endpoints: Tumor reduction by aspirated dissolved tumor volume and Radiologic tumor volume reduction. Started Feb 2018; status: recruiting.
02
Drugs
bromelainacetylcysteine
03
Conditions
pseudomyxoma peritonei (PMP)mucinous peritoneal tumorAppendiceal neoplasm
Beyond the preview
Go deeper on ACTRN12617001612303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001612303.